UTHR Q2 2018 Earnings — United Therapeutics Corporation Revenue & Financial Results | Market Cap Arena

UTHRUnited Therapeutics Corporation

$24B

Q2 2018 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$445M-0.0% YoY

Gross Profit

$383M86.1% margin

Operating Income

$217M48.9% margin

Net Income

$173M38.9% margin

EPS (Diluted)

$3.98

QoQ Revenue Growth

+14.2%

Cash Flow

Operating Cash Flow

$180M

Free Cash Flow

$126M

Stock-Based Comp.

$21M

Balance Sheet

Total Assets

$3.2B

Total Liabilities

$660M

Stockholders' Equity

$2.6B

Cash & Equivalents

$746M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$445M	$445M	-0.0%
Gross Profit	$383M	$426M	-10.1%
Operating Income	$217M	$89M	+145.6%
Net Income	$173M	-$56M	+408.8%

Revenue Segments

Remodulin

$160M36%

Adcirca

$110M25%

Tyvaso

$106M24%

Orenitram

$50M11%

Unituxin

$20M4%

Geographic Segments

U

$422M95%

European Union And Others

$22M5%